Patents Assigned to University of Louisiana at Monroe
  • Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
    Patent number: 9765115
    Abstract: The chain of events that explains calcitonin receptor (CTR)-stimulated invasion and metastasis of prostate cancer cells was identified. The CTR-stimulated events depend on the interaction of CTR with the PDZ3 domain of ZO-1. Small peptides and small molecules were identified that inhibit this interaction. The small inhibitory peptides were synthesized and can be used to attenuate or inhibit metastasis in solid cancer tumors.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 19, 2017
    Assignee: Board of Supervisors of Louisiana State University acting on behalf of the University of Louisiana at Monroe
    Inventor: Girish V. Shah
  • Ceramide-Rubusoside Nanomicelles and Their Use in Cancer Therapy
    Publication number: 20170216329
    Abstract: Water-soluble, cell-permeable nanomicelles containing ceramides and a steviol glycoside, such as rubusoside, are disclosed. The ceramide-steviol glycoside complex has high water solubility, and can be used for treating cancers with p53 mutations. Preliminary results have shown that the Cer nanomicelles are effective in restoring p53 protein expression, and that they are functionally dominant over p53 mutants. The novel nanomicelles restore a wild-type phenotype, and have very low toxicity to noncancerous cells. The novel Cer nanomicelles may be used in treating p53-associated cancers.
    Type: Application
    Filed: May 6, 2015
    Publication date: August 3, 2017
    Applicants: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, University of Louisiana at Monroe
    Inventors: Zhijun Liur, Yong-Yu Liu
  • Anti-cancer hydantoin compounds and methods
    Patent number: 8188130
    Abstract: The present invention relates to methods of either treating or preventing cancer and novel compositions relevant to that treatment and prevention. More particularly, this invention relates to compounds which share features with (Z)-5-(4-hydroxybenzylidene)imidazolidine-2,4-dione and (Z)-5-(4-S-ethylbenzylidene)imidazolidine-2,4-dione and anti-cancer uses for those compounds. Embodiments of the present invention include methods that have anti-cancer effects including anti-metastatic, anti-growth, and anti-invasive activities.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: May 29, 2012
    Assignee: University of Louisiana at Monroe
    Inventors: Girish Shah, Khalid El Sayed
  • Anticancer tobacco cembranoids
    Patent number: 7977384
    Abstract: In the specification and drawings a method of treating cancer is described and shown. The method includes delivering an amount of at least one compound to an area containing a cancer cell. A compound and a method of preparing a compound are also described and shown.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: July 12, 2011
    Assignee: The University of Louisiana at Monroe
    Inventors: Khalid El Sayed, Girish Shah, Paul Sylvester
  • Human cancer cell specific gene transcript
    Patent number: 7713693
    Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel Neuroendocrine-like marker (NELM) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression, diagnosis, and response to therapy of prostate cancer, as well as identifying compounds that promote prostate cancer are described.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: May 11, 2010
    Assignee: University of Louisiana at Monroe
    Inventor: Girish Shah